Annexon Biosciences

Through pioneering research on the classical complement pathway, Annexon is developing a pipeline of first-in-class inhibitors of C1q, the initiating molecule of the classical pathway, that have shown to block synaptic loss, neuronal degradation and inflammation in neurogenerative disease, as well as blocking aberrant auto-antibody attacks in autoimmune disorders.

Area of focus: Complement-mediated neurodegenerative diseases (CMND) in neurological and ophthalmic diseases, and aberrant antibody-mediated attacks in the periphery that result in autoimmune disorders.
Commencement date: January 2015
Location: JLABS @ SSF